Kiniksa Pharmaceuticals Ltd (KNSA)
16.89
+0.02
(+0.12%)
USD |
NASDAQ |
Apr 19, 16:00
16.89
0.00 (0.00%)
After-Hours: 16:00
Kiniksa Pharmaceuticals PE Ratio: 93.83 for April 19, 2024
PE Ratio Chart
Historical PE Ratio Data
| Date | Value |
|---|---|
| April 18, 2024 | 93.72 |
| April 17, 2024 | 94.17 |
| April 16, 2024 | 97.00 |
| April 15, 2024 | 96.89 |
| April 12, 2024 | 96.06 |
| April 11, 2024 | 98.33 |
| April 10, 2024 | 96.94 |
| April 09, 2024 | 98.50 |
| April 08, 2024 | 98.22 |
| April 05, 2024 | 99.44 |
| April 04, 2024 | 100.33 |
| April 03, 2024 | 101.33 |
| April 02, 2024 | 104.06 |
| April 01, 2024 | 109.44 |
| March 28, 2024 | 109.61 |
| March 27, 2024 | 111.06 |
| March 26, 2024 | 110.94 |
| March 25, 2024 | 110.89 |
| March 22, 2024 | 110.94 |
| March 21, 2024 | 110.00 |
| March 20, 2024 | 109.89 |
| March 19, 2024 | 109.44 |
| March 18, 2024 | 108.78 |
| March 15, 2024 | 111.06 |
| March 14, 2024 | 113.06 |
| Date | Value |
|---|---|
| March 13, 2024 | 113.67 |
| March 12, 2024 | 113.56 |
| March 11, 2024 | 113.00 |
| March 08, 2024 | 115.61 |
| March 07, 2024 | 118.11 |
| March 06, 2024 | 116.67 |
| March 05, 2024 | 112.11 |
| March 04, 2024 | 112.17 |
| March 01, 2024 | 120.78 |
| February 29, 2024 | 117.44 |
| February 28, 2024 | 113.11 |
| February 27, 2024 | 116.06 |
| February 26, 2024 | 112.00 |
| February 23, 2024 | 111.11 |
| February 22, 2024 | 109.56 |
| February 21, 2024 | 110.89 |
| February 20, 2024 | 110.67 |
| February 16, 2024 | 110.78 |
| February 15, 2024 | 112.06 |
| February 14, 2024 | 110.50 |
| February 13, 2024 | 110.33 |
| February 12, 2024 | 114.17 |
| February 09, 2024 | 112.67 |
| February 08, 2024 | 105.67 |
| February 07, 2024 | 100.67 |
Price to Earnings Ratio (PE Ratio) Definition
The Price to Earnings Ratio (PE Ratio) is calculated by taking the stock price / EPS Diluted (TTM). This metric is considered a valuation metric that confirms whether the earnings of a company justifies the stock price. There isn't necesarily an optimum PE ratio, since different industries will have different ranges of PE Ratios. Because of this, PE Ratio is great to evaluate from a relative standpoint with other similar companies.
PE Ratio Range, Past 5 Years
3.769
Minimum
Apr 05 2023
120.78
Maximum
Mar 01 2024
29.19
Average
5.618
Median
Jan 13 2023
PE Ratio Benchmarks
| Amicus Therapeutics Inc | -- |
| Geron Corp | -- |
| United Therapeutics Corp | 11.99 |
| Vanda Pharmaceuticals Inc | 97.65 |
| TG Therapeutics Inc | 1379.00 |
PE Ratio Related Metrics
| PS Ratio | 4.522 |
| Price to Book Value | 2.718 |
| Price to Free Cash Flow | 92.78 |
| Price | 16.89 |
| Earnings Yield | 1.07% |
| Market Cap | 1.193B |
| Normalized PE Ratio | 93.83 |